Sangamo Therapeutics (SGMO) 10-Q2013 Q1 Quarterly report

Filed: 9 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: alliance, altogether, back, benchmark, benchmarking, capture, Chemical, chemistry, closing, component, documentation, exon, FASB, formulation, Global, HIV, inconclusive, inflection, instability, integrate, issuer, labor, listed, lysosomal, matrix, model, NASDAQ, newly, prioritize, priority, reclassified, recommendation, reference, regularly, SCD, sector, service, sickle, skipping, standard, subsidiary, suspension, thalassemia, twelve, unforeseen

Removed: acquired, activate, advanced, analyst, assure, attracting, called, circulating, Codification, commitment, consecutive, contract, corrected, correction, culmination, decided, defective, discontinue, effector, establishing, factor, Fox, gaining, GDNF, glial, glioblastoma, heavily, interested, leave, liver, maintaining, Michael, mitigate, MJFF, moderate, multiforme, neurotrophic, Parkinson, pay, performing, permanent, person, placebo, practice, prominence, promise, recurrent, reimburse, renewed, retaining, retire, satisfy, secreted, shown, stop, subcontracted, sublicensable, trained, transient, withdraw, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SGMO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant to 18 U.S.C. §1350, as Adopted

Pursuant to §906 of the Sarbanes-Oxley Act of 2002

Each of the undersigned hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 in his capacity as an officer of Sangamo BioSciences, Inc. (the “Company”), that:

(1) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2013, as filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward O. Lanphier II

Edward O. Lanphier II

President and Chief Executive Officer

(Principal Executive Officer)

Date: May 9, 2013

/s/ H. Ward Wolff

H. Ward Wolff

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

Date: May 9, 2013

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.